The Histone Acetylation Modifications of Breast Cancer and Their Therapeutic Implications

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2018 Jun 28

PMID 29948617

Citations 56

Authors

Pingping Guo

Wenqi Chen

Huiyu Li

Meiying Li

Lisha Li

Affiliations

Soon will be listed here.

Abstract

The histone acetylation modifications (HAMs) influence a large number of cellular functions. They are mediated through histone acetyltransferase (HAT) and histone deacetylase (HDAC). Nowadays, people have realized that HAMs are crucial for development and prognosis of breast cancer. Investigations about abnormal HAMs in breast cancer focus on initiating molecular mechanisms in breast cancer development, identification of new biomarkers to predict breast cancer aggressiveness and the therapeutic potential. As HAMs are reversible, breast cancer may be treated by restoring HAMs to normal levels. Indeed, some HDAC inhibitors have been approved by the US Food and Drug Administration to treat certain cancers. Furthermore, HAT inhibitors, HAT activators and HDAC activators may also be used as drugs to treat breast cancer.

Citing Articles

Unlocking the epigenetic code: new insights into triple-negative breast cancer.

Mahendran G, Shangaradas A, Romero-Moreno R, Wickramarachchige Dona N, Sarasija S, Perera S Front Oncol. 2025; 14:1499950.

PMID: 39744000 PMC: 11688480. DOI: 10.3389/fonc.2024.1499950.

Bio-Pathological Functions of Posttranslational Modifications of Histological Biomarkers in Breast Cancer.

Neagu A, Josan C, Jayaweera T, Morrissiey H, Johnson K, Darie C Molecules. 2024; 29(17).

PMID: 39275004 PMC: 11397409. DOI: 10.3390/molecules29174156.

Acetylation of Steroidogenic Acute Regulatory Protein Sensitizes 17β-Estradiol Regulation in Hormone-Sensitive Breast Cancer Cells.

Manna P, Molehin D, Ahmed A, Yang S, Reddy P Int J Mol Sci. 2024; 25(16).

PMID: 39201419 PMC: 11354777. DOI: 10.3390/ijms25168732.

Multi-faceted regulation of CREB family transcription factors.

Chowdhury M, Haq M, Lee J, Jeong S Front Mol Neurosci. 2024; 17:1408949.

PMID: 39165717 PMC: 11333461. DOI: 10.3389/fnmol.2024.1408949.

Crosstalk between SUMOylation and other post-translational modifications in breast cancer.

Wei B, Yang F, Yu L, Qiu C Cell Mol Biol Lett. 2024; 29(1):107.

PMID: 39127633 PMC: 11316377. DOI: 10.1186/s11658-024-00624-3.

References

Falahi F, van Kruchten M, Martinet N, Hospers G, Rots M . Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer. Breast Cancer Res. 2014; 16(4):412. PMC: 4303227. DOI: 10.1186/s13058-014-0412-z. View

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi G, Ordentlich P . A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. Breast Cancer Res Treat. 2014; 146(2):259-72. PMC: 4119423. DOI: 10.1007/s10549-014-3014-7. View

Gajer J, Furdas S, Grunder A, Gothwal M, Heinicke U, Keller K . Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis. 2015; 4:e137. PMC: 4338425. DOI: 10.1038/oncsis.2014.51. View

Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T . Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 2015; 5(4):1519-30. PMC: 4473328. View

Min A, Im S, Kim D, Song S, Kim H, Lee K . Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Breast Cancer Res. 2015; 17:33. PMC: 4425881. DOI: 10.1186/s13058-015-0534-y. View

Basse C, Arock M . The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. Int J Cancer. 2014; 137(12):2785-94. DOI: 10.1002/ijc.29347. View

Yokoyama Y, Matsumoto A, Hieda M, Shinchi Y, Ogihara E, Hamada M . Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity. Breast Cancer Res. 2014; 16(3):R66. PMC: 4229880. DOI: 10.1186/bcr3681. View

Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M . Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013; 24 Suppl 8:viii75-viii82. DOI: 10.1093/annonc/mdt316. View

Salvador M, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E . The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res. 2013; 19(23):6520-31. DOI: 10.1158/1078-0432.CCR-13-0877. View

10.

Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z . Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat. 2012; 137(1):93-107. PMC: 3637924. DOI: 10.1007/s10549-012-2332-x. View

11.

Derr R, van Hoesel A, Benard A, Goossens-Beumer I, Sajet A, Dekker-Ensink N . High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer. 2014; 14:604. PMC: 4148956. DOI: 10.1186/1471-2407-14-604. View

12.

Cody J, Markert J, Hurst D . Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells. PLoS One. 2014; 9(3):e92919. PMC: 3961437. DOI: 10.1371/journal.pone.0092919. View

13.

Federico M, Bagella L . Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2010; 2011:475641. PMC: 3004414. DOI: 10.1155/2011/475641. View

14.

Dastjerdi M, Salahshoor M, Mardani M, Hashemibeni B, Roshankhah S . The effect of CTB on P53 protein acetylation and consequence apoptosis on MCF-7 and MRC-5 cell lines. Adv Biomed Res. 2013; 2:24. PMC: 3748634. DOI: 10.4103/2277-9175.108005. View

15.

Kochan D, Kovalchuk O . Circadian disruption and breast cancer: an epigenetic link?. Oncotarget. 2015; 6(19):16866-82. PMC: 4627279. DOI: 10.18632/oncotarget.4343. View

16.

Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K . Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol. 2015; 47(6):2073-81. PMC: 4665753. DOI: 10.3892/ijo.2015.3213. View

17.

Raha P, Thomas S, Thurn K, Park J, Munster P . Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015; 17:26. PMC: 4367983. DOI: 10.1186/s13058-015-0533-z. View

18.

Khan S, Aumsuwan P, Khan I, Walker L, Dasmahapatra A . Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome. Chem Res Toxicol. 2011; 25(1):61-73. DOI: 10.1021/tx200378c. View

19.

Secci D, Carradori S, Bizzarri B, Bolasco A, Ballario P, Patramani Z . Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors. Bioorg Med Chem. 2014; 22(5):1680-9. DOI: 10.1016/j.bmc.2014.01.022. View

20.

Chatterjee N, Wang W, Conklin T, Chittur S, Tenniswood M . Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells. Cancer Biol Ther. 2013; 14(7):658-71. PMC: 3742495. DOI: 10.4161/cbt.25088. View